United Therapeutics (UTHR) Free Cash Flow (2009 - 2026)

United Therapeutics has disclosed Free Cash Flow across 18 years of filings, most recently posting $205.6 million for Q2 2026.

• In Q2 2026, Free Cash Flow rose 58.76% year-over-year to $205.6 million; the TTM figure through Jun 2026 stood at $1.1 billion (up 2.05% YoY), while the FY2025 annual figure was $1.0 billion, down 3.69% from the prior year.
• Free Cash Flow came in at $205.6 million for Q2 2026 at United Therapeutics, down from $362.5 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of $386.3 million in Q1 2025 to a low of $61.6 million in Q2 2023.
• Average Free Cash Flow over 5 years is $227.8 million, with a median of $230.0 million recorded in 2024.
• Year-over-year, Free Cash Flow slumped 44.0% in 2023 and soared 253.47% in 2024.
• Over 5 years, Free Cash Flow stood at $88.7 million in 2022, then dropped by 18.83% to $72.0 million in 2023, then soared by 253.47% to $254.5 million in 2024, then slumped by 31.91% to $173.3 million in 2025, then advanced by 18.64% to $205.6 million in 2026.
• Per Business Quant data, the three most recent Free Cash Flow figures were $205.6 million in Q2 2026, $362.5 million in Q1 2026, and $173.3 million in Q4 2025.